Limits...
Protective effect of ligustrazine on lumbar intervertebral disc degeneration of rats induced by prolonged upright posture.

Liang QQ, Ding DF, Xi ZJ, Chen Y, Li CG, Liu SF, Lu S, Zhao YJ, Shi Q, Wang YJ - Evid Based Complement Alternat Med (2014)

Bottom Line: To determine the effect of ligustrazine on disc degeneration, we applied a rat model.We found that pretreatment with ligustrazine for 1 month recovered the structural distortion of the degenerative disc; inhibited the expression of type X collagen, matrix metalloproteinase (MMP)-13, and MMP3; upregulated type II collagen; and decreased IL-1 β , cyclooxygenase (COX)-2, and inducible nitric oxide synthase (iNOS) expression.In conclusion, ligustrazine is a promising agent for treating lumbar intervertebral disc degeneration disease.

View Article: PubMed Central - PubMed

Affiliation: Institute of Spine, Shanghai University of Traditional Chinese Medicine, 725 Wan-Ping South Road, Shanghai 200032, China ; Department of Orthopaedics & Traumatology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

ABSTRACT
Most chronic low back pain is the result of degeneration of the lumbar intervertebral disc. Ligustrazine, an alkaloid from Chuanxiong, reportedly is able to relieve pain, suppress inflammation, and treat osteoarthritis and it has the protective effect on cartilage and chondrocytes. Therefore, we asked whether ligustrazine could reduce intervertebral disc degeneration. To determine the effect of ligustrazine on disc degeneration, we applied a rat model. The intervertebral disc degeneration of the rats was induced by prolonged upright posture. We found that pretreatment with ligustrazine for 1 month recovered the structural distortion of the degenerative disc; inhibited the expression of type X collagen, matrix metalloproteinase (MMP)-13, and MMP3; upregulated type II collagen; and decreased IL-1 β , cyclooxygenase (COX)-2, and inducible nitric oxide synthase (iNOS) expression. In conclusion, ligustrazine is a promising agent for treating lumbar intervertebral disc degeneration disease.

No MeSH data available.


Related in: MedlinePlus

Immunohistochemical assessments of the protein level of type II collagen. Positive staining of type II collagen declined in the nucleus pulposus at all time points after the surgery. Ligustrazine treatment completely reversed the decreased trend of type II collagen at the nucleus pulposus, while meloxicam has no obvious increasing effect. The arrow indicates the positive staining cells; the arrow head indicates the negative staining cells. Bar equals 100 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4020374&req=5

fig3: Immunohistochemical assessments of the protein level of type II collagen. Positive staining of type II collagen declined in the nucleus pulposus at all time points after the surgery. Ligustrazine treatment completely reversed the decreased trend of type II collagen at the nucleus pulposus, while meloxicam has no obvious increasing effect. The arrow indicates the positive staining cells; the arrow head indicates the negative staining cells. Bar equals 100 μm.

Mentions: It was reported that type II collagen is an important component of extracellular matrix of IVDs and plays an essential biomechanical function in the normal disc [18–22]. Thus, we examined type II collagen protein expression by immunohistochemical staining. We found strong immunoreactivity for type II collagen in the nucleus pulposus in control samples. Much weaker immunostaining for type II collagen was observed at any time points in the model group. The density of the type II collagen-positive staining of the ligustrazine group increased dramatically compared to the model group. Meloxicam had no effect on the protein expression of type II collagen (see Figure 3).


Protective effect of ligustrazine on lumbar intervertebral disc degeneration of rats induced by prolonged upright posture.

Liang QQ, Ding DF, Xi ZJ, Chen Y, Li CG, Liu SF, Lu S, Zhao YJ, Shi Q, Wang YJ - Evid Based Complement Alternat Med (2014)

Immunohistochemical assessments of the protein level of type II collagen. Positive staining of type II collagen declined in the nucleus pulposus at all time points after the surgery. Ligustrazine treatment completely reversed the decreased trend of type II collagen at the nucleus pulposus, while meloxicam has no obvious increasing effect. The arrow indicates the positive staining cells; the arrow head indicates the negative staining cells. Bar equals 100 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4020374&req=5

fig3: Immunohistochemical assessments of the protein level of type II collagen. Positive staining of type II collagen declined in the nucleus pulposus at all time points after the surgery. Ligustrazine treatment completely reversed the decreased trend of type II collagen at the nucleus pulposus, while meloxicam has no obvious increasing effect. The arrow indicates the positive staining cells; the arrow head indicates the negative staining cells. Bar equals 100 μm.
Mentions: It was reported that type II collagen is an important component of extracellular matrix of IVDs and plays an essential biomechanical function in the normal disc [18–22]. Thus, we examined type II collagen protein expression by immunohistochemical staining. We found strong immunoreactivity for type II collagen in the nucleus pulposus in control samples. Much weaker immunostaining for type II collagen was observed at any time points in the model group. The density of the type II collagen-positive staining of the ligustrazine group increased dramatically compared to the model group. Meloxicam had no effect on the protein expression of type II collagen (see Figure 3).

Bottom Line: To determine the effect of ligustrazine on disc degeneration, we applied a rat model.We found that pretreatment with ligustrazine for 1 month recovered the structural distortion of the degenerative disc; inhibited the expression of type X collagen, matrix metalloproteinase (MMP)-13, and MMP3; upregulated type II collagen; and decreased IL-1 β , cyclooxygenase (COX)-2, and inducible nitric oxide synthase (iNOS) expression.In conclusion, ligustrazine is a promising agent for treating lumbar intervertebral disc degeneration disease.

View Article: PubMed Central - PubMed

Affiliation: Institute of Spine, Shanghai University of Traditional Chinese Medicine, 725 Wan-Ping South Road, Shanghai 200032, China ; Department of Orthopaedics & Traumatology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

ABSTRACT
Most chronic low back pain is the result of degeneration of the lumbar intervertebral disc. Ligustrazine, an alkaloid from Chuanxiong, reportedly is able to relieve pain, suppress inflammation, and treat osteoarthritis and it has the protective effect on cartilage and chondrocytes. Therefore, we asked whether ligustrazine could reduce intervertebral disc degeneration. To determine the effect of ligustrazine on disc degeneration, we applied a rat model. The intervertebral disc degeneration of the rats was induced by prolonged upright posture. We found that pretreatment with ligustrazine for 1 month recovered the structural distortion of the degenerative disc; inhibited the expression of type X collagen, matrix metalloproteinase (MMP)-13, and MMP3; upregulated type II collagen; and decreased IL-1 β , cyclooxygenase (COX)-2, and inducible nitric oxide synthase (iNOS) expression. In conclusion, ligustrazine is a promising agent for treating lumbar intervertebral disc degeneration disease.

No MeSH data available.


Related in: MedlinePlus